China's Qiming's fifth U.S. dollar venture fund clocks in at $648 million in commitments

Shanghai-based Qiming Venture Partners raised $648 million in commitments for its fifth U.S. dollar venture capital fund, putting its assets under management at $2.5 billion since a debut in 2006 to focus on a mix of China healthcare-related firms among other investments such as mobile phone maker Xiaomi, the company said in a release. "Qiming's portfolio includes over 160 investments distributed among its targeted sectors. Qiming Venture Partners invests in early-stage and expansion-stage deals, with over 50% of its investments in early stage companies," according to the release. The capital raising effort was flagged last week in a press release that noted Qiming's managing partner responsible for the healthcare fund, Nisa Leung, had invested in companies such as Shanghai-based ZAI Lab, which recently cleared $100 million-plus in a Series B round. Release

Suggested Articles

The Shire bid Takeda’s been discussing is getting real. The Japanese drugmakers is gauging lender interest in financing the buy.

After initial doubts, some analysts now like Takeda's chances of pulling off a deal for embattled Shire.

Daiichi Sankyo, which has struggled since losing exclusivity for its blood pressure drug Benicar, is cutting another 280 jobs in the U.S.